Clinical Trial Update: A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of GW679769 sponsored by GlaxoSmithKline for Social Anxiety Disorder and related anxiety disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Social Anxiety Disorder

Drugs mentioned

• GW679769

Snippet

Sponsor: GlaxoSmithKline | Conditions: Social Anxiety Disorder, Anxiety Disorders | Phase 2 | Status: COMPLETED